Four-week pegylated interferon a-2a monotherapy for chronic hepatitis C with genotype 2 and low viral load: A pilot, randomized study

Tsubota, Akihito; Satoh, Keisuke; Aizawa, Mashu; Takamatsu, Seishi; Namiki, Yoshihisa; Ohkusa, Toshifumi; Fujise, Kiyotaka; Tajiri, Hisao

doi:10.3748/wjg.14.7220

Cited by 4 publications

(2 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Slope (95% CI) 1. 22 Compared to the conventional pegylated interferon products, e.g., peginterferon alfa-2a, ropeginterferon alfa-2b had a higher drug exposure at the same dose level, i.e., 180 µg [3,4]. At the same 180 µg dose level, ropeginterferon alfa-2b showed higher C max , AUC 0-t , and AUC 0-inf than peginterferon alfa-2a [3,4].…”

Section: Dose Proportionality Analysis Ln (Auc 0-inf )mentioning

confidence: 93%

“…Pegylated IFN alfa therapies have been shown to induce clinically appreciable sustained virologic responses (SVRs) in CHC patients, e.g., a 70-90% SVR rate in patients with the genotype 2 infection [21][22][23]. In addition, they also alleviate fibrosis and reduce the risk of HCC development in CHC patients [24][25][26].…”

Section: Ropeginterferon Alfa-2b In Chronic Hepatitis C (Chc)mentioning

confidence: 99%

See 1 more Smart Citation

Novel Pegylated Interferon for the Treatment of Chronic Viral Hepatitis

Huang

Qin²,

Tsai³

et al. 2022

Viruses

View full text Add to dashboard Cite

Ropeginterferon alfa-2b is a novel mono-pegylated and extra-long-acting interferon, being developed for the treatment of myeloproliferative neoplasm (MPN) and chronic viral hepatitis. It has a favorable pharmacokinetic profile and less frequent dosing schedule, i.e., once every two to four weeks, compared to conventional pegylated interferon products, which have multiple isomers and are administered weekly. It was approved for the long-term treatment of polycythemia vera, an MPN, and has been included in the NCCN clinical practice guidelines for this indication. Ropeginterferon alfa-2b has demonstrated efficacy and showed a favorable safety profile for the treatment of chronic viral hepatitis in several clinical studies. In this article, we review its pharmacokinetics and available clinical data and suggest that ropeginterferon alfa-2b administered once every two weeks can serve as a new treatment option for patients with chronic viral hepatitis, including chronic hepatitis B, C, and D.

show abstract

Section: Dose Proportionality Analysis Ln (Auc 0-inf )mentioning

confidence: 93%

Section: Ropeginterferon Alfa-2b In Chronic Hepatitis C (Chc)mentioning

confidence: 99%

Novel Pegylated Interferon for the Treatment of Chronic Viral Hepatitis

Huang

Qin²,

Tsai³

et al. 2022

Viruses

View full text Add to dashboard Cite

show abstract

The Predictive Value of On-treatment Virological Response for Sustained Virological Response in Chronic Hepatitis C Patients Receiving a Personalized Treatment Program

Li¹,

Xie²,

Lu³

et al. 2013

Infection International

View full text Add to dashboard Cite

Objective To investigate the effects of individualised treatment with peginterferon alpha-2a (40 kD) plus ribavirin in Chinese patients with CHC. Methods Total of 297 consecutive Chinese patients were enrolled, including 250 naïve cases and 47 cases who were previously treated. Treatment duration was determined according to viral genotypes, prior treatment history and viral responses at week 4, 12 and 24. Results Totally, 235 patients (79.1%) completed treatment and 186 (87.3%) achieved SVR. And 219 out of 289 (75.8%) patients achieved HCV RNA negative at week 4 (RVR) and 259 of 276 (93.8%) at week 12. Among the 164 patients with RVR who completed follow-up, 158 (96.3%) achieved SVR. Patients with RVR had lower baseline viral loads than patients without RVR (P = 0.034). The positive predictive value (PPV) of RVR for SVR was 90.7% (OR 2.10 vs. non-RVR, 95% CI: 0.50 - 8.7). Similar outcomes were observed among patients with HCV undetectable at week 12. Conclusions Complete viral suppression by week 4 is associated with a high rate of treatment success in treatment naïve and experienced patients receiving individualized CHC therapy.

show abstract

Response-guided therapy based on reaction to the initial dose using administration of peginterferon α-2a alone or in combination with ribavirin in naïve patients with chronic hepatitis C of serotype 2 and high viral loads

Kato¹,

Yonezawa²,

Tachibana³

et al. 2012

Kanzo

View full text Add to dashboard Cite

Four-week pegylated interferon a-2a monotherapy for chronic hepatitis C with genotype 2 and low viral load: A pilot, randomized study

Abstract: Our results show that a 4-wk course of peg-IFN-alpha 2a monotherapy can achieve a high SVR rate in "IFN-sensitive" patients, without negatively affecting outcome.

Cited by 4 publications

References 29 publications

Novel Pegylated Interferon for the Treatment of Chronic Viral Hepatitis

Novel Pegylated Interferon for the Treatment of Chronic Viral Hepatitis

The Predictive Value of On-treatment Virological Response for Sustained Virological Response in Chronic Hepatitis C Patients Receiving a Personalized Treatment Program

Response-guided therapy based on reaction to the initial dose using administration of peginterferon α-2a alone or in combination with ribavirin in naïve patients with chronic hepatitis C of serotype 2 and high viral loads

Contact Info

Product

Resources

About